Rhinomed Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNO.AX research report →
Price Chart
About the company
Headquartered in Cremorne, Australia, Rhinomed Limited is a global enterprise dedicated to the research, development, and market introduction of consumer and medical devices. Since its incorporation in 2004, the company has focused on creating wearable nasal technologies designed to optimize breathing, improve sleep quality, support general health, and assist in disease diagnosis. Its product offerings include the Turbine, which enhances athletic breathing; Mute, aimed at reducing snoring and promoting clearer airflow; Pronto, a vapor inhaler developed to aid airflow and sleep; and Rhinoswab, utilized for efficient nasal sample collection.
- CEO
- Michael Johnson
- IPO
- 2007
- HQ
- Cremorne, VIC, AU
Get TickerSpark's AI analysis on RNO.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.47M
- P/E
- -1.05
- PEG
- -0.01
- P/S
- 1.54
- P/B
- -1.78
- EV/EBITDA
- -1.90
- Div Yield
- 0.00%
- Gross Margin
- -2.55%
- Op Margin
- -133.67%
- Net Margin
- -145.98%
- ROE
- 1591.14%
- ROIC
- 2753.17%
Latest fiscal year · YoY change
- Revenue
- $7.47M-17.9%
- Gross Profit
- $-190,440-111.7%
- Op Income
- $-9,988,460
- Net Income
- $-10,908,255-106.6%
- EPS
- $-0.04-89.1%
- OCF Growth
- -25.0%
- FCF Growth
- -9.9%
- 52W High
- $0.10
- 52W Low
- $0.02
- 50D MA
- $0.03
- 200D MA
- $0.05
- Beta
- 0.88
- RSI (14)
- 65
- Avg Volume
- 284.13K
No earnings-call transcripts are available for RNO.AX yet.
- Free Float
- 25.8%
- Shares Outstanding
- 286.78M
- Float Shares
- 74.04M
of shares held by institutions
1 13F filers
Our RNO.AX coverage
Recent articles, reports, and earnings notes.
No research on RNO.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RNO.AX report →